France (FR)

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Sensitivity of CO oxidation toward metal oxidation state in ceria-supported catalysts: an operando DRIFTS-MS study (2016) Kaftan A, Kollhoff F, Thanh-Son Nguyen , Piccolo L, Laurina M, Libuda J Journal article Transduction of Herpesvirus saimiri-Transformed T Cells with Exogenous Genes of Interest (2016) Martínez-Barricarte R, De Jong SJ, Markle J, De Paus R, Boisson-Dupuis S, Bustamante J, Van de Vosse E, et al. Journal article Conodonts from the Lower Ordovician of Morocco – a contribution to the faunal diversity in the famous Fezouata Lagerstätte (2016) Lehnert O, Nowak H, Sarmiento G, Servais T, Gutiérrez-Marco JC, Akodad M Journal article Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution OBSERVATIONAL STUDY OF OUTCOME IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS TREATED WITH IMMUNOSUPPRESSIVE THERAPIES (ESOS STUDY) (2016) Herrick AL, Pan X, Peytrignet S, Hesselstrand R, Mouthon L, Brown E, Czirjak L, et al. Conference contribution INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS (2016) Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries PM, Bannert B, Becker K, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution On a Boltzmann mean field model for knowledge growth (2016) Burger M, Lorz A, Wolfram MT Journal article